|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang D, Ding L, Wang L, Zhao Y, Sun Z,
Karnes RJ, Zhang J and Huang H: LncRNA MALAT1 enhances oncogenic
activities of EZH2 in castration-resistant prostate cancer.
Oncotarget. 6:41045–41055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Misawa A, Takayama K, Urano T and Inoue S:
Androgen-induced long noncoding RNA (lncRNA) SOCS2-AS1 promotes
cell growth and inhibits apoptosis in prostate Cancer Cells. J Biol
Chem. 291:17861–17880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Işın M, Uysaler E, Özgür E, Köseoğlu H,
Şanlı Ö, Yücel ÖB, Gezer U and Dalay N: Exosomal IncRNA-p21 levels
may help to distinguish prostate cancer from benign disease. Front
Genet. 6:1682015.PubMed/NCBI
|
|
6
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng
R, Wang Y, Huang J, Xu M, Yan J and Yu J: lncRNA H19/miR-675 axis
represses prostate cancer metastasis by targeting TGFBI. FEBS J.
281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang JX, Zhai JF, Yang XT and Wang J:
MicroRNA-132 inhibits migration, invasion and
epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in
human non-small cell lung cancer. Eur Rev Med Pharmacol Sci.
20:3793–3801. 2016.PubMed/NCBI
|
|
8
|
Zhou Q, Zhu Y, Wei X, Zhou J, Chang L, Sui
H, Han Y, Piao D, Sha R and Bai Y: MiR-590-5p inhibits colorectal
cancer angiogenesis and metastasis by regulating nuclear factor
90/vascular endothelial growth factor A axis. Cell Death Dis.
7:e24132016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui Z and Hu Y: MicroRNA-124 suppresses
Slug-mediated lung cancer metastasis. Eur Rev Med Pharmacol Sci.
20:3802–3811. 2016.PubMed/NCBI
|
|
10
|
Zhi Y, Pan J, Shen W, He P, Zheng J, Zhou
X, Lu G, Chen Z and Zhou Z: Ginkgolide B inhibits human bladder
cancer cell migration and invasion through MicroRNA-223-3p. Cell
Physiol Biochem. 39:1787–1794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zuo J, Wang D, Shen H, Liu F, Han J and
Zhang X: MicroRNA-153 inhibits tumor progression in esophageal
squamous cell carcinoma by targeting SNAI1. Tumour Biol. Oct
13–2016.(Epub ahead of print). View Article : Google Scholar :
|
|
12
|
Mo W, Zhang J, Li X, Meng D, Gao Y, Yang
S, Wan X, Zhou C, Guo F, Huang Y, et al: Identification of novel
AR-targeted microRNAs mediating androgen signalling through
critical pathways to regulate cell viability in prostate cancer.
PLoS One. 8:e565922013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fletcher CE, Dart DA, Sita-Lumsden A,
Cheng H, Rennie PS and Bevan CL: Androgen-regulated processing of
the oncomir miR-27a, which targets prohibitin in prostate cancer.
Hum Mol Genet. 21:3112–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kroiss A, Vincent S, Decaussin-Petrucci M,
Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J and Allioli
N: Androgen-regulated microRNA-135a decreases prostate cancer cell
migration and invasion through downregulating ROCK1 and ROCK2.
Oncogene. 34:2846–2855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hua X, Xiao Y, Pan W, Li M, Huang X, Liao
Z, Xian Q and Yu L: miR-186 inhibits cell proliferation of prostate
cancer by targeting GOLPH3. Am J Cancer Res. 6:1650–1660.
2016.PubMed/NCBI
|
|
16
|
Wang Y, Shao N, Mao X, Zhu M, Fan W, Shen
Z, Xiao R, Wang C, Bao W, Xu X, et al: MiR-4638-5p inhibits
castration resistance of prostate cancer through repressing
Kidins220 expression and PI3K/AKT pathway activity. Oncotarget.
7:47444–47464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi XB, Ma AH, Xue L, Li M, Nguyen HG,
Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ and deVere
White RW: miR-124 and androgen receptor signaling inhibitors
repress prostate cancer growth by downregulating androgen receptor
splice variants, EZH2, and Src. Cancer Res. 75:5309–5317. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin W, Pan Y, Zheng X, Li D, Bu J, Xu C,
Tang J, Cui R, Lin P and Yu X: MicroRNA-124 regulates TGF-α-induced
epithelial-mesenchymal transition in human prostate cancer cells.
Int J Oncol. 45:1225–1231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lü L, Yuan JD, Cao ZL, Huang T, Zhang CH,
Wang L and Zeng FQ: MiR-124 suppresses the proliferation of human
prostate cancer PC3 cells by targeting PKM2. Zhonghua Nan Ke Xue.
20:495–499. 2014.(In Chinese). PubMed/NCBI
|
|
20
|
Sato S, Katsushima K, Shinjo K, Hatanaka
A, Ohka F, Suzuki S, Naiki-Ito A, Soga N, Takahashi S and Kondo Y:
Histone deacetylase inhibition in prostate cancer triggers
miR-320-mediated suppression of the androgen receptor. Cancer Res.
76:4192–4204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen F, Zhu HH, Zhou LF, Wu SS, Wang J and
Chen Z: Inhibition of c-FLIP expression by miR-512-3p contributes
to Taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol
Rep. 23:1457–1462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu X, Gao G, Chu K, Yang X, Ren S, Li Y,
Wu H, Huang Y and Zhou C: Inhibition of RAC1-GEF DOCK3 by
miR-512-3p contributes to suppression of metastasis in non-small
cell lung cancer. Int J Biochem Cell Biol. 61:103–114. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
25
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi N, Park J, Lee JS, Yoe J, Park GY,
Kim E, Jeon H, Cho YM, Roh TY and Lee Y:
miR-93/miR-106b/miR-375-CIC-CRABP1: A novel regulatory axis in
prostate cancer progression. Oncotarget. 6:23533–23547. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Lieberman R, Pan J, Zhang Q, Du M,
Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, et al: miR-375
induces docetaxel resistance in prostate cancer by targeting SEC23A
and YAP1. Mol Cancer. 15:702016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu L, Zhong J, Guo B, Zhu Q, Liang H, Wen
N, Yun W and Zhang L: miR-96 promotes the growth of prostate
carcinoma cells by suppressing MTSS1. Tumour Biol. 37:12023–12032.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jalava SE, Urbanucci A, Latonen L,
Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL
and Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is
overexpressed in castration-resistant prostate cancer. Oncogene.
31:4460–4471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiao L, Deng Z, Xu C, Yu Y, Li Y, Yang C,
Chen J, Liu Z, Huang G, Li LC and Sun Y: miR-663 induces
castration-resistant prostate cancer transformation and predicts
clinical recurrence. J Cell Physiol. 229:834–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wallis CJ, Gordanpour A, Bendavid JS,
Sugar L, Nam RK and Seth A: MiR-182 is associated with growth,
migration and invasion in prostate cancer via suppression of FOXO1.
J Cancer. 6:1295–1305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Larne O, Östling P, Haflidadóttir BS,
Hagman Z, Aakula A, Kohonen P, Kallioniemi O, Edsjö A, Bjartell A,
Lilja H, et al: miR-183 in prostate cancer cells positively
regulates synthesis and serum levels of prostate-specific antigen.
Eur Urol. 68:581–588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu Z, He B, He J and Mao X: Upregulation
of miR-153 promotes cell proliferation via downregulation of the
PTEN tumor suppressor gene in human prostate cancer. Prostate.
73:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Murata T, Takayama K, Katayama S, Urano T,
Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y,
et al: miR-148a is an androgen-responsive microRNA that promotes
LNCaP prostate cell growth by repressing its target CAND1
expression. Prostate Cancer Prostatic Dis. 13:356–361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Q, Zhao X, Zhang H, Yuan H, Zhu M,
Sun Q, Lai X, Wang Y, Huang J, Yan J and Yu J: MiR-130b suppresses
prostate cancer metastasis through down-regulation of MMP2. Mol
Carcinog. 54:1292–1300. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ottman R, Levy J, Grizzle WE and
Chakrabarti R: The other face of miR-17-92a cluster, exhibiting
tumor suppressor effects in prostate cancer. Oncotarget.
7:73739–73753. 2016.PubMed/NCBI
|
|
38
|
Yanagi T, Nagai K, Shimizu H and Matsuzawa
SI: Melanoma antigen A12 regulates cell cycle via tumor suppressor
p21 expression. Oncotarget. 8:68448–68459. 2017.PubMed/NCBI
|
|
39
|
Prasad R and Katiyar SK: Down-regulation
of miRNA-106b inhibits growth of melanoma cells by promoting
G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1
protein. Oncotarget. 5:10636–10649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:(Database Issue). D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Horoszewicz JS, Leong SS, Kawinski E, Karr
JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of
human prostatic carcinoma. Cancer Res. 43:1809–1818.
1983.PubMed/NCBI
|
|
43
|
Seim I, Jeffery PL, Thomas PB, Nelson CC
and Chopin LK: Whole-genome sequence of the metastatic PC3 and
LNCaP human prostate cancer cell lines. G3 (Bethesda). 7:1731–1741.
2017.PubMed/NCBI
|
|
44
|
Chen W, Liu Y, Chen H, Ning H and Ding K:
Loss of miR-449a-caused PrLZ overexpression promotes prostate
cancer metastasis. Int J Oncol. 51:435–444. 2017.PubMed/NCBI
|
|
45
|
Zhou Y, Ji Z, Yan W, Zhou Z and Li H: The
biological functions and mechanism of miR-212 in prostate cancer
proliferation, migration and invasion via targeting Engrailed-2.
Oncol Rep. 38:1411–1419. 2017.PubMed/NCBI
|
|
46
|
Lu S, Wang MS, Chen PJ, Ren Q and Bai P:
miRNA-186 inhibits prostate cancer cell proliferation and tumor
growth by targeting YY1 and CDK6. Exp Ther Med. 13:3309–3314. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang YQ, Ling XH, Yuan RQ, Chen ZY, Yang
SB, Huang HX, Zhong WD and Qiu SP: miR-30c suppresses prostate
cancer survival by targeting the ASF/SF2 splicing factor
oncoprotein. Mol Med Rep. 16:2431–2438. 2017.PubMed/NCBI
|
